SPARC collaborates with HitGen
13th Mar 2019

Sun Pharma Advanced Research Company (SPARC) and HitGen have collaborated to identify novel small molecule leads for targets of interest. Under this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for SPARC.

Under the terms of the agreement, HitGen will receive upfront payment and will be eligible for certain milestone payments.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.